TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Cirrhosis defined by any one of the following~   1. Cirrhosis on liver biopsy or transient wave elastography~  2. Nodular liver on imaging~  3. Endoscopic or radiological evidence of varices in a patient with chronic liver disease~  4. Platelet count \<150,000/mm3 and AST/ALT ratio \>1 in a patient with chronic liver disease~  5. Patients with frank decompensation (ascites, HE, variceal bleeding, hepato-pulmonary syndrome)~3. Prior HE controlled on standard of care therapy defined as lactulose or rifaximin for at least 2 months prior to enrollment.~4. Serum albumin \<4 gm/dl~5. Cognitive impairment on any of the three testing strategies for HE including Psychometric hepatic encephalopathy score (PHES), Stroop test and Critical Flicker Frequency~   1. PHES aggregate score \<-4SD based on norms published in Allampati et al located at the website www.encephalapp.com~  2. Stroop OffTime+OnTime values greater than norms published in Allampati et al located at the website www.encephalapp.com~  3. Critical Flicker Frequency value \<39 Hz~Exclusion Criteria:~1. Unclear diagnosis of cirrhosis (does not meet the criteria outlined above)~2. No prior overt HE episodes~3. HE uncontrolled on standard of care defined as a mini-mental status exam\<25~4. On regular IV albumin infusions due to scheduled paracentesis within the last 3 months~5. Recent alcohol abuse (within 3 months)~6. Unable to give consent~7. Current or recent invasive bacterial or fungal infections (\<1 month)~8. Allergic reactions to IV albumin~9. Current or recent congestive heart failure (Systolic ejection fraction \<25%) within the last year~10. Pregnancy (positive urine pregnancy test at screening)~11. In the opinion of the PI, those who are unlikely to survive 6 weeks or be able to adhere to the trial activities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV albumin (Type: EXPERIMENTAL): 25% IV albutein (albumin) formulation will be infused 1.0g/kg IV over one hour weekly for 5 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline will be infused 1.0g/kg IV over one hour weekly for 5 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indocyanine Green for Central Nervous System Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients 18 years of age and older Patients presenting with a CNS tumor presumed to be resectable and are at risk for local recurrence on pre-operative assessment Good operative candidate as determined by the treating physician and multidisciplinary team Subject capable of giving informed consent and participating in the process of consent~Exclusion Criteria:~Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery Subjects with a history of iodide allergies Vulnerable patient populations Patients unable to participate in the consent process (children and neonates) Patients with non-MRI compatible implanted metallic foreign bodies Patients who due to severe claustrophobia cannot tolerate MRI scanning Patients with a known allergy or hypersensitivity to MRI contrast agents including gadolinium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICG Arm (Type: EXPERIMENTAL): Subjects undergo indocyanine green injection within 72 hours prior to surgery. Permitting infusion time within 72 hours of operation is believed to be adequate for tissue glow/surgical visualization. Alternately, patients may receive 25 mg of indocyanine green during induction. Dose and time of administration will be determined by the neurosurgeon during surgical planning. This 25 mg dose of indocyanine green is similar to dosing for other intraoperative vascular visualization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Music Therapy on Breastfeeding Among Mothers of Premature Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mothers of premature newborns, with birth weight ≤ 1750 g that have reached clinical stability defined by the medical staff.~* To have signed an informed consent to participate in the study.~Exclusion Criteria:~* Mothers that are HIV (Human Immunodeficiency Virus) positive.~* Mothers of neonates with clinical problems that impaired breast suction (encephalopathy with serious hypotonus, oro-facial anomalies, and heart problems).~* Mothers with severe hearing deficiencies.~Exit Criteria:~* Mothers whose neonates died during the hospital stay.~* Mothers who, for any reason, had three or less music therapy sessions.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Music therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intervention to Promote Breast Cancer Screening Among American Indian Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are self-identified AI women of the YST in SD~* Women who are aged 40 to 70 years~* Women who have not received a mammogram in the past two years~* Women who are willing to use their own mobile phone, iPad, tablets, and computers, or a mobile phone borrowed from the research team for the wMammogram intervention.~Exclusion Criteria:~* Women who received a mammogram in the past year~* Women who are under 40 or over 70 years of age.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants are randomized to interventional arm which is seven-day intervention that requires them to download mobile app to complete educational courses each day. There are pre and post tests to complete and a follow up focus group six month after intervention. The intervention encourages education on mammogram needs.
- Control (Type: NO_INTERVENTION): Participants are randomized to control arm where they are give an education brochure. There are pre and post tests to complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected subjects 18 years of age or older~* Receiving HAART for at least two years~* At least a viral load determination per year since HAART initiation, all undetectable~* Patient's status is Immunological Non Responder (InR), that is, his or her viral load is reduced, but CD4+ cell count has not raised accordingly~* Current viral load: undetectable~* Patient agrees and signs informed consent~Exclusion Criteria:~* Concomitant active infectious or neoplastic disease~* History of new AIDS-defining events during HAART~* Pregnancy or breast-feeding~* Patients who have been subjects of an investigational agent, chemotherapy or radiotherapy within the previous 28 days~* Subjects requiring treatment for Tuberculosis~* Subjects unable to follow, or comply with the protocol interventions~* Subjects receiving immunosuppressive treatment, including corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Obstructive Pulmonary Disease Patient Preferences Survey

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of COPD~* English or French speaking~* Patient at one of the three participating sites with medical chart~Exclusion Criteria:~* No diagnosis of COPD by a healthcare professional~* Unable to communicate in English or French~* Unable to provide informed consent~* No medical chart information at one of the three participating sites

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Quartile 1 [Mild] (Type: None): None
- Quartile 2 [Moderate] (Type: None): None
- Quartile 3 [Severe] (Type: None): None
- Quartile 4 [Very Severe] (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes whose glycaemia was not optimally controlled with current therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 users (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycine vs Placebo for the Schizophrenia Prodrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meet SIPS criteria for schizophrenia prodrome~Exclusion Criteria:~* history of psychosis

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Glycine (Type: EXPERIMENTAL): Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing \> 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have schizophrenia and be experiencing a psychotic episode~* Each patient must have a level of understanding sufficient to complete all tests and examinations required by the protocol, and to provide informed consent~* Patient must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to the study entry~* Female patients must not be pregnant or breast-feeding~* Female patients must not be experiencing acute, serious or unstable medical conditions other than schizophrenia~Exclusion Criteria:~* Patients who were previously treated with olanzapine and are considered to be treatment-resistant to olanzapine, in the opinion of the investigator~* One or more seizures without a clear and resolved etiology is exclusionary. However, if the patient has had one or more seizures in the past with an identifiable etiology, and that etiology has been resolved, the patient may be entered.~* Treatment with clozapine within 4 weeks prior to visit 1~* DSM-IV or DSM-IV-TR substance (except nicotine and caffeine) dependence within the past 30 days~* Treatment with remoxipride within 6 months (180 days) prior to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years old woman,~* Documented HIV-1 seropositive,~* CD4 count greater than 200,~* Not on HIV antiretroviral therapy,~* HSV-2 seropositive as determined by Focus EIA (IN \>3.5)~* Not intending to move out of the area for the duration of study participation.~* Willing and able to:provide independent written informed consent;undergo clinical evaluations;take study drug as directed;adhere to follow-up schedule.~* Bacterial STDs (symptomatic STD syndromes or laboratory-confirmed asymptomatic gonorrhea and syphilis) are treated within two weeks of study enrollment and random assignment.~Exclusion Criteria:~Women who meet any of the following criteria are not eligible for this study:~* Known history of adverse reaction to valacyclovir, acyclovir or famciclovir;~* Planned open label use of acyclovir, valacyclovir, or famciclovir~* Known medical history of seizures~* Known renal failure, serum creatinine \>2.0mg/dl~* Hematocrit \< 30 %

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Age ≥18 years old~2. Willing and capable of interacting with the informed consent process~3. Primary disorder being a persistent rocking dizziness triggered by passive motion such as from water, land, or air travel and with no other central nervous system or peripheral vestibular disorder determined after appropriate evaluation.~Exclusion criteria:~1. Subjects who cannot comply with study conditions.~2. Active psychiatric condition such as mania or psychosis~3. Unstable medical condition~4. Implanted metal anywhere in the body (infusion pumps, pacemakers, metal or shrapnel in the body, deep brain stimulators, aneurysm clips, metal prostheses, joints, rods or plates). Dental fillings are acceptable.~5. Personal history of seizures or a first-degree relative with epilepsy~6. Medications known to lower seizure threshold such as: typical (high-potency) neuroleptics and tricyclic antidepressants: Subjects who take one or a combination of the following drugs will be excluded: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine. clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine (including MDMA, ecstasy), phencyclidine (PCP, angel's dust), ketamine, gamma-hydroxybutyrate (GHB), theophylline, haloperidol, fluphenazine, bupropion.~7. Pregnancy or planning to become pregnant during study enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Target 1: Occipital Cortex (Type: EXPERIMENTAL): After determination of the motor threshold, the TMS coil will be positioned over the midline occipital cortex using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
- Target 2: Cerebellar Vermis (Type: EXPERIMENTAL): After determination of the motor threshold, the TMS coil will be positioned over the midline cerebellar vermis using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.
- Target 3: Cerebellar Hemisphere (Type: ACTIVE_COMPARATOR): After determination of the motor threshold, the TMS coil will be positioned over the lateral cerebellar hemisphere using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses in continuous theta burst mode will be delivered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. In the opinion of the investigator, is capable of understanding and complying with protocol requirements.~2. Signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.~3. Is a healthy male or female and aged 19 to 55 years, inclusive, at the time of informed consent and first study medication dose.~4. Weighs at least 45 kilogram (kg) and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening.~5. A female of non-bearing potential (example post-menopausal by history; or history of hysterectomy, bilateral salpingectomy, or oophorectomy).~Exclusion Criteria:~1. Have a known history or evidence of a clinically significant disorder (including neurologic and psychiatric), or disease that in the opinion of the study investigator would pose a risk to the participant safety or interfere with the study evaluation, procedures or completion.~2. Contraindication to magnetic resonance imaging (MRI) based on the standard MRI radiography screening questionnaire.~3. Had exposure to any radiation greater than (\>) 15 millisievert (mSv)/year (example, occupational or radiation therapy) within the previous year prior to Baseline imaging.~4. Has a known hypersensitivity to any component of the formulation of TAK-935 or related compounds, or to \[18F\]MNI-792 or to any of its components.~5. Clinically significant abnormal findings on brain MRI scan or findings on brain MRI that may interfere with the interpretation of the PET imaging.~6. Use of any over-the-counter, herbal, or prescription medications or supplements within 30 days prior to baseline imaging.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- TAK-935 (Type: EXPERIMENTAL): A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of \[18F\]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Healthy male aged 18 to 45 years with a BMI between 18 and 30 kg/m2, (inclusive).~Exclusion Criteria:~* Standard exclusion criterion for Phase 1 clinical trial in healthy subjects.~* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate~* History or presence of GI, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs as judged by Investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Single ascending dose (Type: PLACEBO_COMPARATOR): Single dose of SUVN-G3031or placebo in healthy male subjects
- Multiple ascending dose (Type: PLACEBO_COMPARATOR): Multiple doses of SUVN-G3031 or placebo in healthy male subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete